News

Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.

Each 2021 ACCC Innovator Award program recipient will deliver a presentation on its winning program at ACCC’s 38th National Oncology Conference, according to the organization.

A phase 1b/2 study has shown an 80% clinical activity rate with liposomal annamycin as treatment of soft tissue sarcoma lung metastases.

Sarah P. Psutka, MD, discussed the efficacy and toxicity of later-line ICI and TKI therapy in mRCC during an interview with Targeted Oncology.

N-803 in combination with BCG has demonstrated disease-free survival benefit in patients with NMIBC. This meets the primary end point of the QUILT 3.032 study.

Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma.

A study at MD Anderson Cancer Center aims to evaluate ixazomib and rituximab in patients with relapsed or refractory mantle cell lymphoma.

New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.

In combination with chemotherapy and sintilimab, a bevacizumab biosimilar injection was found to increase PFS in patients with Nonsquamous NSCLC who progressed after a prior EGFR-TKI.

In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.

Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.

The HIMALAYA study has met its primary end point of overall survival improvement in patients with unresectable hepatocellular carcinoma with tremelimumab plus durvalumab.

LAVA-051 for the treatment of CLL was granted an orphan drug designation by the FDA. Results of a phase 1 study of the agent are expected in the first half of 2022.

Richard Anderson, PhD, discusses the effects lymphoma treatments have on fertility.

The new state-of-the-art North Port Cancer Center is now open.

Currently, no FDA-approved therapies are available to address the need of patients with advanced/recurrent endometrial cancer, underscoring a need to develop novel strategies like the combination of lenvatinib and weekly paclitaxel.

Despite researchers compiling data from an equal-access system and adjusting for age, diagnosis period, tumor stage, tumor histology/grade, and whether the patient had adjuvant treatment, the overall survival disparity between Black and White women with endometrial cancer persisted.

The combination had a 24-month OS rate of 80%.

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the safety profile of larotrectinib in thyroid cancer and other solid tumors.

Three medical oncologists from Florida Cancer Specialists are co-authors on a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Obinutuzumab is associated with greater toxicity compare to rituximab in follicular lymphoma.

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, discussed a multiple trial analysis of patients treated with larotrectinib over a median of 24 months.

The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma.

Pembrolizumab is now FDA approved in combination with chemotherapy and with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.

A new database organizes information on driver mutations for researchers.

The combination of abemaciclib and endocrine therapy has been approved by the FDA as an adjuvant treatment for a subgroup of patients with hormone receptor-positive, HER2-negative, node-positive, early breast cancer.

In an interview with Targeted Oncology, Jason Westin, MD, discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.

A novel ATR inhibitor displayed early signals of activity and was tolerable in patients with solid tumor harboring various molecular alterations.

Following a safety evaluation, the FDA has lifter its clinical hold of studies of rusfertide.